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Identity 
Other names: PEZ, PTP36 




The PTPN14 gene consists of 19 exons and 21 introns 
divided over 203 kb, including a coding region and 5' 
and 3' non-coding regions. 
Transcription 
The PTPN14 transcript is processed into a mature 
mRNA in excess of 10 kb, estimated by Northern blot
analysis (Smith et al., 1995). The mature transcript has 
a 3561 nucleotide open reading frame and ~9,2 kb 3' 
UTR followed by a polyadenylation site. No transcript 
variants have been identified. 
Little investigation has been undertaken to elucidate the 
factors regulating PTPN14 transcription. However, 
real-time PCR and ChIP sequencing have shown that 
p63 induces PTPN14 expression by binding to a p63 
consensus sequence within intron 3 of PTPN14 (Perez 
et al., 2007). 
 
Genomic and transcript structure of human PTPN14. A. The genomic arrangement of PTPN14 with vertical bars depicting the 
location and relative size of exons. Space between exons depicts relative sizes of introns/non-coding regions. B. The mature transcript 
arrangement of PTPN14. Exons are numbered and coding regions are depicted in light brown, with non-coding regions depicted in red. 
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PTPN14 is an 1187 amino acid non-receptor protein 
tyrosine phosphatase of approximately 135 kDa. It 
possesses an N-terminal FERM (band 4.1, ezrin, 
radixin, moesin homology) domain and C-terminal 
catalytic domain, as well as acidic and proline-rich 
regions in its central uncharacterised region (Smith et 
al., 1995). 
FERM domain: the FERM domain has been shown in 
other proteins to be important for cytoskeletal 
association; however a role for the FERM domain in 
the PTPN14 protein has yet to be described. 
Catalytic PTP domain: the crystal structure of the 
PTPN14 catalytic C-terminal PTP domain has been 
solved (Barr et al., 2006). 
PPxY motifs: Pez contains two PPxY motifs in its 
central region. These motifs are known to facilitate 
binding to proteins containing WW domains. Indeed, 
both PPxY motifs in PTPN14 are critical for binding 
KIBRA and YAP, components of the Hippo signalling 
pathway that contain WW domains (Liu et al., 2013; 
Poernbacher et al., 2012). 
Mitochondrial localisation signal: PTPN14 contains a 
putative mitochondrial localisation signal (MitoProt II), 
and may be localised to mitochondria in some cell 
types (Chao et al., 2011). 
Localisation 
PTPN14 protein has been reported to localise to 
adherens junctions in confluent human umbilical vein 
endothelial cells (HUVEC) and translocate to the 
nucleus in sub-confluent, proliferating HUVEC  
(Wadham et al., 2000; Wadham et al., 2003). 
Localisation to the golgi apparatus in epithelial cell 
types (Wyatt and Khew-Goodall, 2008) and 
mitochondria in human sperm has also been reported 
(Chao et al., 2011). 
Function 
PTPN14 intracellular signaling pathways/processes 
Adherens junction integrity: PTPN14 protein has 
been reported to dephosphorylate the adherens junction 
protein beta-catenin. Over-expression of a dominant-
negative form of PTPN14 caused an increase in 
phosphorylation at adherens junctions (Wadham et al., 
2003), an event linked to adherence junction 
destabilisation. 
TGF-β: PTPN14 promotes epithelial-mesenchymal 
transition (EMT) via increased TGF-beta production in 
MDCK epithelial cells (Wyatt et al., 2007) 
Lymphangiogenesis: PTPN14 forms a complex with 
VEGFR3 and is required for normal 
lymphangiogenesis in human and mouse models (Au et 
al., 2010). 
Hippo signalling: PTPN14 has been shown to interact 
with Kibra/WWC1 (Poernbacher et al., 2012; Wang et 
al., 2012) and YAP (Liu et al., 2013; Huang et al., 
2012; Wang et al., 2012), two members of the Hippo 
signalling pathway.  
In Drosophila, PTPN14 interacts with Kibra via a 
PPxY:WW domain interaction, to negatively regulate 
the transcriptional activity of the downstream effector 
Yorkie, resulting in a decrease in intestinal stem cell
proliferation (Poernbacher et al., 2012).  
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Protein structure of PTPN14. A schematic of PTPN14 protein highlighting putative nuclear / mitochondrial localisation signals (red/grey 
box), the band 4.1 ezrin, radixin, meosin (FERM) homology domain (red), and the tyrosine-phosphatase (PTP) catalytic domain (blue). 
The linker region also contains an acidic region as well as two PPxY motifs. 
 
Expression of PTPN14. 
 
Pez interacts with YAP (the mammalian homolog of 
Drosophila Yorkie), also via a PPxY:WW domain 
interaction, and regulates its activity by controlling 
YAP cytoplasmic retention (resulting in a loss of 
transcription of YAP target genes) (Liu et al., 2013, 
Huang et al., 2012, Wang et al., 2012). 
Mast cell degranulation: PTPN14 siRNA mediated 
knock-down in mast cells caused a decrease in IgE 
dependent mast cell degranulation (Zhang et al., 2010). 
Homology 
PTPN14 belongs to a FERM domain-containing family 
of non-receptor protein tyrosine phosphatases including  
PTPN3 (PTPH1), PTPN4 (PTP-MEG1), PTPN13 
(PTP-BAS / FAP-1) and PTPN21 (PTPD2). PTPN14 
displays a higher degree of homology to PTPN21 than
other members of this sub-family (Smith et al., 1995; 
Alonso et al., 2004). 
Mutations 
Germinal 
A deletion in PTPN14 has been described in a kindred 
with inherited lymphedema-choanal atresia syndrome, 
characterised by defects in lymphatic vasculature (Au 
et al., 2010). 
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Somatic 
Missense mutations in PTPN14 have been reported in 
sporadic human colorectal cancers (Wang et al., 2004), 
breast cancers (Sjöblom et al., 2006), and HCV-




Several studies have identified mutations associated 
with PTPN14 in colorectal (Wang et al., 2004), breast 
(Sjöblom et al., 2006) and liver cancers (Li et al., 
2011), although the functional consequences of these 
mutations are yet to be determined. 
Colorectal cancer 
Note 
PTPN14 has been shown to interact with and de-
phosphorylate residue Y128 of p130 Crk-associated 
substrate (p130Cas) in colorectal cancer cells (CRC) 
(Zhang et al., 2012). CRC homozygous for a  
non-phosphorylatable Y128F mutant form of p130Cas 
display a reduction in migration,anchorage-independent 
growth and xenograft tumor growth in nude mice, 
suggesting that Pez, via p130Cas Y128 
dephosphorylation, may function as a tumour 
suppressor in colorectal cancer. 
Pancreatic cancer 
Note 
PTPN14 expression was found to be lower in liver 
metastases compared to primary tumours in an 
orthotopic transplantation model of pancreatic 
adenocarcinoma (Niedergethmann et al., 2007), 




Over-expression of PTPN14 in epithelial cells (MDCK) 
resulted in increased TGF-beta secretion and 
subsequent induction of epithelial-mesenchymal 
transition (EMT) (Wyatt et al., 2007). 
Sperm motility 
Note 
PTPN14 expression in human sperm was correlated 
with motility, where moderate-motility sperm had less 
PTPN14 expression than highly-motile sperm (Chao et 
al., 2011). 
Lymphedema-choanal atresia syndrome 
Note 
Analyses of a kindred with autosomal-recessive 
lyphedema-choanal atresia syndrome showed a loss of 
function mutation in PTPN14. PTPN14-/- mice 
developed lymphatic hyperplasia with lymphedema.  
PTPN14 was also shown to interact with VEGFR3, a 
signalling receptor essential to lymphangiogenesis (Au 
et al., 2010). 
Hereditary haemorrhagic telangiectasia 
Note 
PTPN14 maps to a chromosomal region that modifies 
the penetrance of a vascular dysgenesis phenotype in 
Tgfb1-/- mice, and can modulate angiogenesis in 3D 
primary endothelial cell culture (Benzinou et al., 2012), 
suggesting that Pez contributes to angiogenesis, 
possibly an interaction with the TGF-beta signalling 
pathway. 
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